NASDAQ
17.12.25 | 21:59
12,075 US-Dollar
-3,40 % -0,425
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data | 1 | Investing.com | ||
| 10.12. | Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants | 3 | Seeking Alpha | ||
| 10.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 08.12. | Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock | 1 | Seeking Alpha | ||
| 08.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12. | Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results | 2 | Benzinga.com | ||
| 08.12. | Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data | 1 | Investing.com | ||
| 08.12. | Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data | 3 | Investing.com | ||
| 08.12. | Goldman Sachs bekräftigt Rating für Fulcrum Therapeutics nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12. | BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data | 3 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright | 2 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results | 4 | Seeking Alpha | ||
| 08.12. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Leerink Partners raises Fulcrum Therapeutics stock price target on strong sickle cell data | 5 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics stock price target raised to $10 from $7 at RBC Capital | 1 | Investing.com | ||
| 06.12. | Fulcrum Therapeutics: Starke Studiendaten für Sichelzell-Medikament Pociredir | 4 | Investing.com Deutsch | ||
| 06.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | 95 | GlobeNewswire (Europe) | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| 05.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 02.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 | 1 | GlobeNewswire (USA) | ||
| 24.11. | Fulcrum Therapeutics stock price target raised to $18 from $12 at H.C. Wainwright | 1 | Investing.com |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| CUREVAC | 3,502 | -14,46 % | Abend-Update: Curevac unter Druck - Anleger verlieren die Nerven! | ||
| MODERNA | 25,940 | +1,97 % | Moderna, Inc.: Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference | CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30... ► Artikel lesen | |
| VALNEVA | 3,568 | -0,17 % | EILMELDUNG: Valneva unter Druck - Anleger verlieren die Nerven! | ||
| AMGEN | 278,50 | +0,16 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,600 | +0,52 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 303,10 | +1,24 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| BIOGEN | 146,30 | +0,24 % | HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress | ||
| ILLUMINA | 110,52 | -1,29 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,200 | -0,84 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 636,00 | +0,13 % | 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow | ||
| SANGAMO THERAPEUTICS | 0,380 | +0,74 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,155 | -4,08 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| EDITAS MEDICINE | 2,192 | +2,38 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
FULCRUM THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,40 % bei einem Aktienkurs von 12,075 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FULCRUM THERAPEUTICS INC finden Sie auf Wallstreet Online.